Contributions
Abstract: P556
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - OCT
Background: Optical coherence tomography (OCT) can measure the retinal layers. In patients with multiple sclerosis (MS), various OCT measures have been correlated with different visual tests, however, it is unclear which measure associates best with clinical visual deficits.
Objectives: To investigate the association between different OCT measures and visual tests in patients with MS.
Methods: Thirty-four patients with RRMS (16 with previous optic neuritis) and 33 controls, matched for age and gender underwent OCT and a clinical visual assessment, including high- and low-contrast letter acuity as well as colour vision testing (Ishihara table and Hardy-Rand-Rittler, HRR, pseudoisochromatic test). Patients and controls were compared for their visual- and OCT-parameters. Correlations between OCT-parameters (thickness of the retinal nerve fiber layer, RNFL; thickness of the papillomacular bundle, PMB; volume of the macula) and visual tests were assessed.
Results: Although patients and controls did not differ significantly regarding their scores in high- and intermediate (2.5%) contrast vision, low (1.25%) contrast letter acuity was significantly lower in MS patients vs. controls (respectively, 23.4±7.6 vs. 29.2±6.6; p=0.002). The Ishihara score was not different between patients and controls, however, the HRR score was significantly lower in MS patients vs. controls (34.97±2.1 vs. 35.97±0.2; p=0.012). Peripapillary RNFL and PMB were significantly thinner in MS patients vs. controls (RNFL: 96.5 mm±10.8 in patients vs. 104 mm±9.25 in controls, p=0.004; PMB: 48.5 mm±9.5 in patients vs. 54.4 mm±6.5 in controls, p=0.005). Macular volume was by trend lower in MS patients (8.66 mm3±0.41 vs. 8.85 mm3±0.41, p=0.072). Among the three OCT measures (macular volume, RNFL- and PMB thickness), PMB thickness showed a moderate correlation to both low-contrast (1.25%) vision (r=0.51, p=0.002) and HRR colour vision (r=0.54, p=0.002). Peripapillary RNFL thickness correlated moderately with HRR (r=0.57, p=0.001), but only by trend with low-contrast (1.25%) vision, while macular volume did not show significant associations with the visual tests.
Conclusions: In this RRMS cohort, atrophy of the papillomacular bundle was the OCT measure associated both with low-contrast- and colour vision. Focus on the PMB thickness instead of using the entire RNFL thickness in MS could increase the sensitivity to detect clinically relevant damage.
Disclosure:
Athina Papadopoulou has received travel Support from Bayer AG, Teva and UCB-Pharma AG and research grant by the University of Basel.
Laura Gaetano was in advisory board of Novartis.
Armanda Pfister has nothing to disclose.
Stefano Magon has received travel support by Biogen.
Martin Hardmeier is supported by the Swiss National Science Foundation (grant 33CM30-140338).
Peter Fuhr has grants from the Parkinson Schweiz, the Jacques and Gloria Gossweiler Foundation, the Freiwillige Akademische Gesellschaft Basel, the Gottfried und Julia Bangerter-Rhyner Foundation, the Swiss National Science Foundation, the Swiss Multiple Sclerosis Society, the Camelia Botnar Foundation, the Hedwig Widmer Foundation and unrestricted grants from: UCB Pharma AG, Roche AG, Abbvie AG, General Electrics; Advisory Board: Biogen inc.
Ludwig Kappos"s institution, the University Hospital Basel, has received research support and payments that were used exclusively for research support for Prof Kappos" activities as principal investigator and member or chair of planning and steering committees or advisory boards in trials sponsored by Actelion, Addex, Almirall, Bayer Health Care Pharmaceuticals, CLC Behring, Genentech, Inc., GeNeuro SA, Genzyme, Merck Serono, Mitsubishi Pharma, Novartis, Octapharma, Ono Pharma, Pfizer, Receptos, F. Hoffmann-La Roche Ltd., Sanofi-Aventis, Santhera, Siemens and Teva, UCB, Xenport; royalties from Neurostatus AG; research grants from the Swiss MS Society, Swiss National Research Foundation, the European Union, Gianni Rubatto Foundation, Novartis Research Foundation and Roche Research foundation.
The current (DKD Helios Klinik Wiesbaden) or previous (University Hospital Basel) institutions of Till Sprenger have received payments for speaking or consulting from: Biogen Idec, Eli Lilly, Allergan, Actelion, ATI, Mitsubishi Pharma, Novartis, Genzyme, and Teva. Dr. Sprenger received research grants from the Swiss MS Society, Novartis Pharmaceuticals Switzerland, EFIC-Grünenthal grant, and Swiss National Science foundation.
Abstract: P556
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - OCT
Background: Optical coherence tomography (OCT) can measure the retinal layers. In patients with multiple sclerosis (MS), various OCT measures have been correlated with different visual tests, however, it is unclear which measure associates best with clinical visual deficits.
Objectives: To investigate the association between different OCT measures and visual tests in patients with MS.
Methods: Thirty-four patients with RRMS (16 with previous optic neuritis) and 33 controls, matched for age and gender underwent OCT and a clinical visual assessment, including high- and low-contrast letter acuity as well as colour vision testing (Ishihara table and Hardy-Rand-Rittler, HRR, pseudoisochromatic test). Patients and controls were compared for their visual- and OCT-parameters. Correlations between OCT-parameters (thickness of the retinal nerve fiber layer, RNFL; thickness of the papillomacular bundle, PMB; volume of the macula) and visual tests were assessed.
Results: Although patients and controls did not differ significantly regarding their scores in high- and intermediate (2.5%) contrast vision, low (1.25%) contrast letter acuity was significantly lower in MS patients vs. controls (respectively, 23.4±7.6 vs. 29.2±6.6; p=0.002). The Ishihara score was not different between patients and controls, however, the HRR score was significantly lower in MS patients vs. controls (34.97±2.1 vs. 35.97±0.2; p=0.012). Peripapillary RNFL and PMB were significantly thinner in MS patients vs. controls (RNFL: 96.5 mm±10.8 in patients vs. 104 mm±9.25 in controls, p=0.004; PMB: 48.5 mm±9.5 in patients vs. 54.4 mm±6.5 in controls, p=0.005). Macular volume was by trend lower in MS patients (8.66 mm3±0.41 vs. 8.85 mm3±0.41, p=0.072). Among the three OCT measures (macular volume, RNFL- and PMB thickness), PMB thickness showed a moderate correlation to both low-contrast (1.25%) vision (r=0.51, p=0.002) and HRR colour vision (r=0.54, p=0.002). Peripapillary RNFL thickness correlated moderately with HRR (r=0.57, p=0.001), but only by trend with low-contrast (1.25%) vision, while macular volume did not show significant associations with the visual tests.
Conclusions: In this RRMS cohort, atrophy of the papillomacular bundle was the OCT measure associated both with low-contrast- and colour vision. Focus on the PMB thickness instead of using the entire RNFL thickness in MS could increase the sensitivity to detect clinically relevant damage.
Disclosure:
Athina Papadopoulou has received travel Support from Bayer AG, Teva and UCB-Pharma AG and research grant by the University of Basel.
Laura Gaetano was in advisory board of Novartis.
Armanda Pfister has nothing to disclose.
Stefano Magon has received travel support by Biogen.
Martin Hardmeier is supported by the Swiss National Science Foundation (grant 33CM30-140338).
Peter Fuhr has grants from the Parkinson Schweiz, the Jacques and Gloria Gossweiler Foundation, the Freiwillige Akademische Gesellschaft Basel, the Gottfried und Julia Bangerter-Rhyner Foundation, the Swiss National Science Foundation, the Swiss Multiple Sclerosis Society, the Camelia Botnar Foundation, the Hedwig Widmer Foundation and unrestricted grants from: UCB Pharma AG, Roche AG, Abbvie AG, General Electrics; Advisory Board: Biogen inc.
Ludwig Kappos"s institution, the University Hospital Basel, has received research support and payments that were used exclusively for research support for Prof Kappos" activities as principal investigator and member or chair of planning and steering committees or advisory boards in trials sponsored by Actelion, Addex, Almirall, Bayer Health Care Pharmaceuticals, CLC Behring, Genentech, Inc., GeNeuro SA, Genzyme, Merck Serono, Mitsubishi Pharma, Novartis, Octapharma, Ono Pharma, Pfizer, Receptos, F. Hoffmann-La Roche Ltd., Sanofi-Aventis, Santhera, Siemens and Teva, UCB, Xenport; royalties from Neurostatus AG; research grants from the Swiss MS Society, Swiss National Research Foundation, the European Union, Gianni Rubatto Foundation, Novartis Research Foundation and Roche Research foundation.
The current (DKD Helios Klinik Wiesbaden) or previous (University Hospital Basel) institutions of Till Sprenger have received payments for speaking or consulting from: Biogen Idec, Eli Lilly, Allergan, Actelion, ATI, Mitsubishi Pharma, Novartis, Genzyme, and Teva. Dr. Sprenger received research grants from the Swiss MS Society, Novartis Pharmaceuticals Switzerland, EFIC-Grünenthal grant, and Swiss National Science foundation.